LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Listă Acțiuni・Novo Nordisk A-S

Novo Nordisk A-S

Închisă

SectorSănătate

45.8 0.11

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

45.75

Maxim

47.05

Indicatori cheie
By Trading Economics
Venit	6.9B 27B
Vânzări	4.2B 79B
P/E Medie Sector	12.162 49.8
Randament dividend	4.11
Marjă de profit	33.977
Angajați	68,794
EBITDA	3.5B 37B

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	-10.04% downside

Dividende
By Dow Jones
Randament dividend Medie Sector	4.11% 2.25%

Statistici piață
By TradingEconomics
Capitalizare de piață	-65B 197B
Deschiderea anterioară	45.69
Închiderea anterioară	45.8

Sentimentul știrilor

By Acuity

27%

73%

68 / 347 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

62.63 / 69.23 Suport & Rezistență

Novo Nordisk A-S Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 mai 2026, 07:30 UTC

Câștiguri

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill -- Update

6 mai 2026, 06:19 UTC

Câștiguri

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill

7 mai 2026, 09:30 UTC

Câștiguri

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6 mai 2026, 12:36 UTC

Câștiguri

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6 mai 2026, 10:53 UTC

Acțiuni populare

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6 mai 2026, 10:12 UTC

Câștiguri

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6 mai 2026, 09:58 UTC

Câștiguri

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

6 mai 2026, 09:35 UTC

Acțiuni populare

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6 mai 2026, 08:13 UTC

Market Talk

Câștiguri

Novo Nordisk Guidance Tweak Unlikely to Drive Upgrades -- Market Talk

6 mai 2026, 07:43 UTC

Market Talk

Câștiguri

Novo Nordisk Consensus Earnings Expectations Likely to Rise -- Market Talk

6 mai 2026, 07:00 UTC

Câștiguri

Novo Nordisk Shares Rise 5.5% After 1Q Results

6 mai 2026, 06:34 UTC

Câștiguri

Novo Nordisk Execs Were Speaking on Media Call After 1Q Earnings

6 mai 2026, 06:26 UTC

Câștiguri

Novo Nordisk CFO: Branded GLP-1 Market is Expanding

6 mai 2026, 06:26 UTC

Câștiguri

Novo Nordisk CFO: Data Indicates There is a Lower Share of Compounders in The Market

6 mai 2026, 06:24 UTC

Câștiguri

Novo Nordisk CFO: Believe We've Found a Sweet Spot in Terms of Pricing With Wegovy Pill

6 mai 2026, 06:20 UTC

Câștiguri

Novo Nordisk CEO: Very Excited By What We See With Wegovy Pill

6 mai 2026, 06:19 UTC

Câștiguri

Novo Nordisk CFO: So Far Competitor's Pill Hasn't Impacted Wegovy Pill Trajectory

6 mai 2026, 06:13 UTC

Câștiguri

Novo Nordisk CEO: Continue To Try and Improve Our Pipeline Internally and Externally

6 mai 2026, 06:13 UTC

Câștiguri

Novo Nordisk CEO: Seen Continued Interest In Our Pill Despite Competitor Entering Market

6 mai 2026, 06:12 UTC

Câștiguri

Novo Nordisk CFO: Impact From Higher Oil Prices is Immaterial to Co

6 mai 2026, 05:43 UTC

Câștiguri

Novo Nordisk: Total Wegovy Pill Prescriptions Since Launch Now Exceed 2M

6 mai 2026, 05:42 UTC

Câștiguri

Novo Nordisk: Total Prescriptions For Wegovy Pill in 1Q Reached Around 1.3M

6 mai 2026, 05:40 UTC

Câștiguri

Novo Nordisk: First Wegovy Pill Launches Outside U.S. Expected During 2H26

6 mai 2026, 05:40 UTC

Câștiguri

Novo Nordisk 1Q Op Margin 61.6%

6 mai 2026, 05:39 UTC

Câștiguri

Novo Nordisk 1Q Gross Margin 85.9%

6 mai 2026, 05:39 UTC

Câștiguri

Novo Nordisk 1Q Wegovy Injectable Sales Rose 12% at CER To DKK 18.24B, Consensus Saw DKK16.85B

6 mai 2026, 05:38 UTC

Câștiguri

Novo Nordisk 1Q Ozempic Drug Sales Fell 8% at CER To DKK27.83B, Consensus Saw DKK26.4B

6 mai 2026, 05:36 UTC

Câștiguri

Novo Nordisk: Analysts Saw 1Q Net Profit At DKK23.3B

6 mai 2026, 05:36 UTC

Câștiguri

Novo Nordisk 1Q Net Pft DKK48.56B

6 mai 2026, 05:36 UTC

Câștiguri

Novo Nordisk: Analysts Saw 1Q Op Pft at DKK49.11B

Comparație

Modificare preț

Novo Nordisk A-S Așteptări

Obiectiv de preț

By TipRanks

-10.04% jos

Prognoză pe 12 luni

Medie 41.2 USD -10.04%

Maxim 47 USD

Minim 36 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruNovo Nordisk A-S - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

8 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 8 analiști care au acordat evaluări ale acțiunilor Novo Nordisk A-S - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

62.63 / 69.23Suport & Rezistență

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

68 / 347 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.